Old Drug Offers New Hope for Kids With Rare BABS Disorder

A decades-old drug once shelved in one fight has suddenly emerged in another, offering rare hope to children facing the devastating genetic disorder Bachmann-Bupp syndrome.

Researchers now report that DFMO, a medicine previously used against sleeping sickness, may do more than blunt symptoms. Early patient treatments suggest it could target the biological malfunction that drives Bachmann-Bupp syndrome, or BABS, an ultra-rare condition that can threaten both development and survival. That possibility matters because families dealing with disorders this rare often confront a brutal reality: few studies, few therapies, and almost no roadmap.

What makes this moment so striking is not just that an old drug may work, but that it appears to act on the root problem behind an ultra-rare disease with almost no treatment options.

The early signals remain just that: early. Reports indicate researchers have treated only a handful of patients so far, and the results have been encouraging rather than definitive. Still, even limited improvement carries weight in a disease this severe, especially when the treatment strategy aims at the underlying genetic error instead of chasing one complication at a time. The story also highlights a growing pattern in medicine, where overlooked drugs gain new life when scientists match them to the mechanics of rare diseases.

That progress has not come easily. Researchers have had to navigate regulatory barriers and practical bottlenecks that often stall rare-disease work long after the science points in a promising direction. In common illnesses, those delays can frustrate. In ultra-rare pediatric disorders, they can define the difference between momentum and lost time. Sources suggest those hurdles, not just the science itself, now shape how quickly this potential therapy can reach more children.

The next phase will matter as much as the early breakthrough. Researchers need broader follow-up, clearer data, and a smoother path through oversight and access challenges before DFMO can move from promising intervention to established care. If those pieces fall into place, this effort could do more than help children with BABS. It could show how medicine can rescue forgotten drugs and turn them into targeted answers for families who have waited far too long.